pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Ciprofloxacin
drug
save

ciprofloxacin

Marketedupdated 3mo ago
by Bedford Laboratories
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval94 co-mentions · 45 sources
  • drugciprofloxacin hydrochloride ER47 co-mentions · 44 sources
  • drugCIPROFLOXACIN HYDROCHLORIDE47 co-mentions · 44 sources
  • tagSmall Molecule43 co-mentions · 43 sources
  • tagRecall4 co-mentions · 4 sources
  • drugdexamethasone SR3 co-mentions · 2 sources
  • drugNEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE2 co-mentions · 1 sources
  • companyLeading Pharma LLC2 co-mentions · 2 sources

all catalysts(1)

phase 1 completion · 1
Apr 30, 2026
phase 1 completion
4mo ago
Johns Hopkins University — ciprofloxacin (Phase I Trial Completion)
ciprofloxacin
→

Trials studying ciprofloxacin

  • —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
  • phase1A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566completedn=60
  • phase2Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Studycompletedn=210
  • phase2PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatmentnot yet recruitingn=206
  • phase2Ciprofloxacin BioThrax Co-Administration Studycompletedn=154
  • phase1A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjectscompletedn=64
  • N/ALiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Mediacompletedn=175
  • phase1Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mgcompletedn=36
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Apr 21, 2029
~2.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

  • Nov 27, 2038formulationUS 11246863
  • Nov 12, 2037method-of-use (U-2252)US 11040004
  • Jul 1, 2035formulationUS 9220796
  • Apr 27, 2030method-of-use (U-1792)US 83188173.7y
  • Dec 11, 2029formulationUS 92330683.3y
  • Apr 21, 2029formulationUS 113695662.7y
  • Apr 21, 2029method-of-use (U-1793)US 92050482.7y
  • Apr 21, 2029compositionUS 96037962.7y

News(0)

no news has mentioned this drug yet

brand
Ciprofloxacin
generic
ciprofloxacin
indication
Septic Arthritis
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 24m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?